Table 4.

Cardiovascular events after the Trials of Hypertension Prevention by categories of urinary sodium excretion (mg/24hr) – Sensitivity analyses adjusting for creatinine.

	Sodium Excretion (mg/24hr)				P Value for Trend	HR per 1000 mg/d	P Value
	<2300	2300– <3600	3600– <4800	≥ 4800
Excluding those with CV Cr/Wt >= 20%* (CVD events/ Total = 104/1298)
HR	0.67	0.83	1.00	1.35	0.14	1.20	0.094
95%CI	0.23–1.91	0.48–1.44	(Reference)	0.76–2.42		0.97–1.50
Excluding those with CV Cr/Wt >= 30%* (CVD events/ Total = 141/1780)
HR	0.71	0.79	1.00	1.00	0.31	1.18	0.078
95%CI	0.30–1.68	0.50–1.24	(Reference)	0.61–1.65		0.98–1.42
Controlling for Cr/Wt in Model (CVD events/ Total = 193/2312)
HR	0.70	0.76	1.00	1.03	0.19	1.16	0.085
95%CI	0.34–1.45	0.51–1.13	(Reference)	0.66–1.60		0.98–1.37
Controlling for CV Cr/Wt in Model* (CVD events/ Total = 180/2218)
HR	0.61	0.72	1.00	1.10	0.066	1.18	0.040
95%CI	0.29–1.28	0.48–1.09	(Reference)	0.71–1.71		1.01–1.39

From Cox proportional hazards regression models stratified by trial phase and adjusted for age, sex, race/ethnicity, clinic, and treatment assignment, education status, baseline weight, alcohol use, smoking, exercise, potassium excretion, and family history of cardiovascular disease, and changes in weight, smoking, and exercise during the trial periods. Cr/wt indicates creatinine/weight ratio; CV, coefficient of variation; HR, hazard ratio; CI, confidence interval.

^*In those with at least 2 urine excretions.